Sprague-dawley and fischer female rats differ in acute effects of fluoxetine on sexual Behavior

Journal of Sexual Medicine

Volumn 10, Issue 2, 2013, Pages 350-361

  Miryala, Chandra Suma J ^a   Hiegel, Cindy ^a   Uphouse, Lynda ^a  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Estrogen; Female sexual behavior; Fluoxetine; Progesterone; Rat strains; SSRI

Indexed keywords

ESTRADIOL BENZOATE; FLUOXETINE; PROGESTERONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IC 50; LORDOSIS QUALITY; LORDOSIS TO MOUNT RATIO; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVARIECTOMY; PRIORITY JOURNAL; RAT; SEXUAL BEHAVIOR; UROGENITAL SYSTEM PARAMETERS;

EID: 84873059926     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02981.x     Document Type: Article

References (65)

1. Simpson K, Noble S. Fluoxetine: A review of its use in women's health. CNS Drugs 2000;14:301-28.
2. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007;19:247-55.
3. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003;13:57-66.
4. Haenisch B, Bonisch H. Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 2010;129:352-68.
5. Auerbach SB, Minzenberg MJ, Wilkinson LO. Extracellular serotonin and 5-hydroxyindoleacetic acid in hypothalamus of the unanesthetized rat measured by in vivo dialysis coupled to high-performance liquid chromatography with electrochemical detection: Dialysate serotonin reflects neuronal release. Brain Res 1989;499:281-90.
6. Dawson LA, Nguyen HQ, Smith DI, Schechter LE. Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: A microdialysis study. Br J Pharmacol 2000;130:797-804.
7. Segraves RT. Sexual dysfunction associated with antidepressant therapy. Urol Clin North Am 2007;34:575-9, vii.
8. Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep 2002;2:182-7.
9. Morehouse R, Macqueen G, Kennedy SH. Barriers to achieving treatment goals: A focus on sleep disturbance and sexual dysfunction. J Affect Disord 2011;132(suppl 1):S14-20.
10. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27-32.
11. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol 2009;29:259-66.
12. Sidi H, Asmidar D, Hod R, Guan NC. Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. J Sex Med 2012;5:976-88.
13. Snoeren EM, Chan JS, de Jong TR, Waldinger MD, Olivier B, Oosting RS. A new female rat animal model for hypoactive sexual desire disorder; behavioral and pharmacological evidence. J Sex Med 2011;8:44-56.
14. Mendelson SD. A review and reevaluation of the role of serotonin in the modulation of lordosis behavior in the female rat. Neurosci Biobehav Rev 1992;16:309-50.
15. Uphouse L. Female gonadal hormones, serotonin, and sexual receptivity. Brain Res Brain Res Rev 2000;33:242-57.
16. Adams S, Heckard D, Hassell J, Uphouse L. Factors influencing fluoxetine-induced sexual dysfunction in female rats. Behav Brain Res 2012;235:73-81.
17. Guptarak J, Sarkar J, Hiegel C, Uphouse L. Role of 5-HT(1A) receptors in fluoxetine-induced lordosis inhibition. Horm Behav 2010;58:290-6.
18. Snoeren EM, Refsgaard LK, Waldinger MD, Olivier B, Oosting RS. Chronic paroxetine treatment does not affect sexual behavior in hormonally sub-primed female rats despite 5-HT(A) receptor desensitization. J Sex Med 2011;8:976-88.
19. Ivarsson M, Paterson LM, Hutson PH. Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats. Eur J Pharmacol 2005;522:63-71.
20. Alahmed S, Herbert J. Strain differences in proliferation of progenitor cells in the dentate gyrus of the adult rat and the response to fluoxetine are dependent on corticosterone. Neuroscience 2008;157:677-82.
21. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004;29:1321-30.
22. Horowitz JM, Hallas BH, Torres G. Rat strain differences to fluoxetine in striatal Fos-like proteins. Neuroreport 2002;13:2463-7.
23. Uphouse L, Hensler JG, Sarkar J, Grossie B. Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats. Brain Res 2006;1072:79-90.
24. Maswood N, Sarkar J, Uphouse L. Modest effects of repeated fluoxetine on estrous cyclicity and sexual behavior in Sprague Dawley female rats. Brain Res 2008;1245:52-60.
25. Uphouse L, Maswood S, Jackson A, Brown K, Prullage J, Myers T, Shaheen F. Strain differences in the response to the 5-HT1A receptor agonist, 8-OH-DPAT. Pharmacol Biochem Behav 2002;72:533-42.
26. Miryala CS, Hassell J, Hiegel C, Uphouse L. Female Fischer and Sprague-Dawley rats differ in fluoxetine-induced sexual dysfunction. 714/15/VV85. Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience; 2011. 2011: Online.
27. White S, Uphouse L. Estrogen and progesterone dose-dependently reduce disruptive effects of restraint on lordosis behavior. Horm Behav 2004;45:201-8.
28. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003;55:597-606.
29. Zar J. Biostatistical analysis. Englewood Cliffs, NJ: Prentice Hall; 1999.
30. Uphouse L, White S, Harrison L, Hiegel C, Majumdar D, Guptarak J, Truitt WA. Restraint accentuates the effects of 5-HT2 receptor antagonists and a 5-HT1A receptor agonist on lordosis behavior. Pharmacol Biochem Behav 2003;76:63-73.
31. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41-100.
32. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203.
33. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: Guilt by association. Neuroscientist 2004;10:575-93.
34. Burnet PW, Michelson D, Smith MA, Gold PW, Sternberg EM. The effect of chronic imipramine administration on the densities of 5-HT1A and 5-HT2 receptors and the abundances of 5-HT receptor and transporter mRNA in the cortex, hippocampus and dorsal raphe of three strains of rat. Brain Res 1994;638:311-24.
35. Rosecrans JA, Robinson SE, Johnson JH, Mokler DJ, Hong JS. Neuroendocrine, biogenic amine and behavioral responsiveness to a repeated foot-shock-induced analgesia (FSIA) stressor in Sprague-Dawley (CD) and Fischer-344 (CDF) rats. Brain Res 1986;382:71-80.
36. Jacobs BL, Klemfuss H. Brain stem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Res 1975;100:450-7.
37. Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Neurobiol 1997;7:820-5.
38. Kosten TA, Ambrosio E. HPA axis function and drug addictive behaviors: Insights from studies with Lewis and Fischer 344 inbred rats. Psychoneuroendocrinology 2002;27:35-69.
39. Armario A, Gavalda A, Marti J. Comparison of the behavioural and endocrine response to forced swimming stress in five inbred strains of rats. Psychoneuroendocrinology 1995;20:879-90.
40. Sarrieau A, Mormede P. Hypothalamic-pituitary-adrenal axis activity in the inbred Brown Norway and Fischer 344 rat strains. Life Sci 1998;62:1417-25.
41. van der Staay FJ, Blokland A. Behavioral differences between outbred Wistar, inbred Fischer 344, brown Norway, and hybrid Fischer 344 x brown Norway rats. Physiol Behav 1996;60:97-109.
42. Robert G, Drapier D, Bentue-Ferrer D, Renault A, Reymann JM. Acute and chronic anxiogenic-like response to fluoxetine in rats in the elevated plus-maze: Modulation by stressful handling. Behav Brain Res 2011;220:344-8.
43. Maswood S, Truitt W, Hotema M, Caldarola-Pastuszka M, Uphouse L. Estrous cycle modulation of extracellular serotonin in mediobasal hypothalamus: Role of the serotonin transporter and terminal autoreceptors. Brain Res 1999;831:146-54.
44. Benmansour S, Piotrowski JP, Altamirano AV, Frazer A. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology 2009;34:555-64.
45. Schneider T, Popik P. Attenuation of estrous cycle-dependent marble burying in female rats by acute treatment with progesterone and antidepressants. Psychoneuroendocrinology 2007;32:651-9.
46. Charoenphandhu J, Teerapornpuntakit J, Nuntapornsak A, Krishnamra N, Charoenphandhu N. Anxiety-like behaviors and expression of SERT and TPH in the dorsal raphe of estrogen- and fluoxetine-treated ovariectomized rats. Pharmacol Biochem Behav 2011;98:503-10.
47. Bertrand PP, Paranavitane UT, Chavez C, Gogos A, Jones M, van den Buuse M. The effect of low estrogen state on serotonin transporter function in mouse hippocampus: A behavioral and electrochemical study. Brain Res 2005;1064:10-20.
48. Eser D, Baghai TC, Schule C, Nothdurfter C, Rupprecht R. Neuroactive steroids as endogenous modulators of anxiety. Curr Pharm Des 2008;14:3525-33.
49. Frye CA, Rhodes ME. Fluoxetine-induced decrements in sexual responses of female rats and hamsters are reversed by 3alpha, 5alpha-THP. J Sex Med 2010;7:2670-80.
50. Jackson A, Uphouse L. Dose-dependent effects of estradiol benzoate on 5-HT1A receptor agonist action. Brain Res 1998;796:299-302.
51. Jackson A, Etgen AM. Estrogen modulates 5-HT(1A) agonist inhibition of lordosis behavior but not binding of [(3)H]-8-OH-DPAT. Pharmacol Biochem Behav 2001;68:221-7.
52. Kacew S, Ruben Z, McConnell RF. Strain as a determinant factor in the differential responsiveness of rats to chemicals. Toxicol Pathol 1995;23:701-14.
53. Wetzel LT, Luempert LG 3rd, Breckenridge CB, Tisdel MO, Stevens JT, Thakur AK, Extrom PJ, Eldridge JC. Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. J Toxicol Environ Health 1994;43:169-82.
54. Rehavi M, Attali G, Gil-Ad I, Weizman A. Suppression of serum gonadal steroids in rats by chronic treatment with dopamine and serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2000;10:145-50.
55. Taylor GT, Farr S, Klinga K, Weiss J. Chronic fluoxetine suppresses circulating estrogen and the enhanced spatial learning of estrogen-treated ovariectomized rats. Psychoneuroendocrinology 2004;29:1241-9.
56. Blaustein JD. Neuroendocrine regulation of feminine sexual behavior: Lessons from rodent models and thoughts about humans. Annu Rev Psychol 2008;59:93-118.
57. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007;12:247-57.
58. Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, Lehtimaki T. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J Neural Transm 2007;114:1065-8.
59. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473-500.
60. Pitychoutis PM, Pallis EG, Mikail HG, Papadopoulou-Daifoti Z. Individual differences in novelty-seeking predict differential responses to chronic antidepressant treatment through sex- and phenotype-dependent neurochemical signatures. Behav Brain Res 2011;223:154-68.
61. Razzoli M, Carboni L, Andreoli M, Michielin F, Ballottari A, Arban R. Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse. Pharmacol Biochem Behav 2011;97:566-76.
62. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006;31:2281-8.
63. Bishop JR, Ellingrod VL, Akroush M, Moline J. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: Possible relationship to oral contraceptives. Hum Psychopharmacol 2009;24:207-15.
64. Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, Souery D, Zobel A, Dernovsek MZ, Streit F, Schmal C, Kozel D, Placentino A, Farmer A, McGuffin P, Aitchison KJ, Rietschel M. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2011;12:528-38.
65. Zourkova A, Hadasova E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J Sex Marital Ther 2002;28:451-61.